NTx Bio
NTx Bio (Nature’s Toolbox, Inc.) is revolutionizing biomanufacturing by enabling on-demand, decentralized, and scalable production of high-quality RNA and proteins. Our mission is to democratize access to medicines by overcoming the bottlenecks of traditional, centralized manufacturing. Through proprietary, synthetic biology platforms like NTxscribe® (mRNA production) and NTxpress® (cell free protein production), NTx empowers researchers and companies to accelerate the development and delivery of personalized and mass-scale therapeutics, making next-generation medicine more accessible, sustainable, and efficient, while eliminating supply chain concerns by using 100% domestic inputs and production capabilities.
NTx Bio
7701 Innovation Way NE, Rio Rancho, NM 87144
What We Do
A benchtop, automated, continuous flow RNA in vitro transcription (IVT) and purification system that produces high-integrity mRNA and saRNA in just 3 hours. Enables scalable, cost-effective, and rapid RNA manufacturing from research to commercial volumes.
A fully recombinant, cell-free protein synthesis platform designed for high-yield, high-purity protein production. Offers rapid, scalable, and reproducible protein manufacturing without the limitations of traditional cell-based or extract-based methods.
Expert mRNA synthesis services using the NTxscribe® continuous flow technology, providing high-quality, high-integrity RNA for research and discovery needs. Services include rapid turnaround, custom sequence design, and comprehensive quality control.
High-end Cryo-EM facility offering sample optimization, image acquisition, data processing, 3D analysis, training, and consulting for high-resolution structural biology research.
Application Area
Regenerative Medicine
Vaccines
Key People
President & Chief Executive Officer
Chief Scientific Officer & Senior Vice President R&D
Chief Financial Officer
Chief Operating Officer
Senior Vice President, Business Development
Vice President, Corporate Development
News & Updates
NTx was recognized as a Top 10 Drug Discovery Company by Pharma Tech Outlook.
NTx raised $47.5 million in Series B funding to accelerate its biomanufacturing platforms.
NTx received a BARDA DRIVe contract to demonstrate its NTxscribe® platform for rapid RNA vaccine manufacturing in collaboration with Houston Methodist Hospital.
NTx is working on materials to improve global access to vaccines, supporting rapid and scalable vaccine manufacturing.
Rio Rancho Mayor discusses the positive economic impact of NTx’s presence in the region.
Site Selection Magazine features NTx as a transformative company in the biomanufacturing sector.
Podcast interview with NTx CEO discussing the company’s mission and technology.
Steven Evans, Ph.D., appointed as CSO to lead R&D and scientific strategy.
Marcel Roche joins as CFO to support NTx’s financial and strategic growth.
Edward Liddy, former Allstate CEO, joins NTx’s Board, bringing significant leadership experience.
A retrospective on NTx’s impact and activities in Rio Rancho, New Mexico.
NTx featured in a news segment highlighting its role in vaccine manufacturing.
Article on NTx’s role in job creation and economic development.
NTxBio will establish a biomanufacturing facility in Plano, Texas, creating over 170 new jobs and more than $31 million in capital investment.
NTx announced the founding of its Scientific Advisory Board with experts from leading cancer centers to guide the company’s RNA manufacturing technology.
Joan Haab, Ph.D., joins NTx as COO, bringing decades of experience in biotech and diagnostics to lead operational and supply chain functions.
NTxscribe benchtop system is now fully commercially available, enabling affordable, scalable, and rapid RNA manufacturing.
NTx secured $15 million in venture debt from J.P. Morgan to support the adoption and expansion of its distributed biomanufacturing systems.
NTx launches services to accelerate mRNA research using its advanced biomanufacturing platforms.